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Abstract
Background: Malignant soft tissue tumors of the foot are extremely rare and thus can be prematurely excised
without appropriate preoperative evaluation. The present study compares adverse effects between unplanned and
planned surgical excisions.
Methods: We retrospectively reviewed the clinical records, radiographs, pathology reports and pathological
specimens of 14 consecutive patients with soft tissue sarcoma of the foot among 592 with sarcomas between
1973 and 2009. We then compared the incidence and clinical outcomes after unplanned (UT; n = 5) and planned
(PT; n = 9) surgical excisions of foot sarcomas.
Results: The most frequent diagnosis was synovial sarcoma (n = 4; 28.6%). The overall 5-year survival rates of the
PT and UT groups were 65.6% and 60.0%, respectively, and the event-free 5-year survival rates were 63.5% and
40.0%, respectively. Event-free and overall survival rates did not significantly differ between the two groups.
However, tumors were significantly larger in the PT group than in the UT group (p < 0.05).
Conclusions: Unplanned resection lead to a relatively worse prognosis and a likelihood of recurrence despite
additional resections. We recommend that soft tumors of the foot should only be excised after appropriate
preoperative evaluation regardless of the size of the tumor.
Background
Soft tissue sarcomas are rare malignancies that account
for < 1% of all adult malignancies that annually develop
in the United States of America [1]. Among them, malig-
nant soft tissue tumors of the foot are extremely rare,
occurring at a rate of 2% to 5% of soft tissue malignancies
[2], whereas benign soft-tissue tumors, such as schwan-
noma, lipomas and hemangiomas, arise more frequently
[3-5].
Soft-tissue sarcomas of the foot and benign tumors are
notoriously difficult to clinically differentiate [6-8], as their
similar presenting features include a palpable mass, swel-
ling, increased warmth, limping and pain. Furthermore,
soft-tissue sarcomas of the foot tend to be relatively smal-
ler than those of the proximal limbs, because discomfort
while wearing shoes results in seeking medical attention.
These non-specific clinical features coupled with the
relative rarity and small size, frequently lead to inadequate
treatment of soft tissue sarcomas of the foot compared
with sarcomas at other anatomical sites [8].
The initial choice of treatment for soft-tissue sarcoma
influences the final oncological outcome [6,9]. Thus, wide
surgical excision of a sarcoma of the foot after diagnostic
imaging, and accurate biopsy is crucial to achieve a good
clinical outcome. However, many potential treatment
errors are associated with soft tissue sarcomas of the foot.
Unplanned surgical excision of a foot sarcoma without
appropriate diagnostic evaluation is quite common
[6,9,10]. Unplanned surgical excision can result in an inap-
propriate surgical margin that will require further wide
surgical excision and residual disease that can cause
repeated local recurrences that can result in limb amputa-
tion or be life-threatening.
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We retrospectively reviewed the medical records, radio-
graphs and pathology reports of 592 patients who pre-
sented at our hospital with soft tissue sarcoma between
1973 and 2009. Among these, we enrolled 14 consecutive
patients with foot sarcoma. The exclusion criteria were
benign tumors, bone tumors, myeloma, lymphoma, meta-
static carcinoma, and tumors arising from the skin. The
mean follow-up period was 56.5 months (range 6 - 170
months) after the initial consultation. The patient group
included 10 males and four females with a mean age of
35.8 (range 2 - 67) years at the first presentation. Clinical
records, radiographs, pathology reports, and pathological
specimens were retrospectively reviewed to compare inci-
dences and clinical outcomes of unplanned (UT group)
and planned (PT group) surgical resections. All histologi-
cal diagnoses were made by our institutional pathologists.
The tumor grade was assessed according to the updated
version of the FNCLCC system based on tumor differen-
tiation, the mitotic count and necrosis [11]. Unplanned
surgical excision was defined as that proceeding without
preoperative imaging evaluation or staging studies. The
cases initially treated by a general surgeon or general
orthopedic surgeon without considering the possibility of
malignancy were classified in the UT group. Among the
UT group patients, extensive hematoma and inappropriate
drainage and improper skin incision were observed in 2, 1
and 5 patients, respectively. In contrast, planned surgical
resection was defined as that proceeding with appropriate
preoperative imaging evaluation. The cases treated by
orthopedic oncologists or treated under the supervision of
an orthopedic oncologist were classified in the PT group.
As a result, there were no patients who showed extensive
hematoma, inappropriate drainage or an improper skin
incision in the PT group. Variables included patient age,
gender, tumor location, grade, surgical margin of initial
surgery, tumor size (≥3c m ,g r o u pB ;<3c m ,g r o u pS ) ,
complications, overall survival rates, event-free survival
rates and limb preservation (yes or no) between the UT
and PT groups. The overall survival was defined as the
time from the initial treatment to the date of death attrib-
uted to sarcoma. The event-free survival was defined as
the time from the initial treatment to the date of clinically
documented local recurrence/distant metastasis. The loca-
tions of soft-tissue sarcomas in the foot were classified
according to the zones described by Kirby et al. [12]. A
transverse plane was drawn from the mid-point of the
metatarsal heads to the level of the insertion point of the
Achilles tendon, and two vertical planes were drawn from
the mid-tarsal point to the posterior end of the longitudi-
nal plantar arch and another from the metatarsophalan-
geal joints down to the sole of the foot. These three lines
form five zones, including the region of the ankle (zone 1),
heel (zone 2), dorsum of foot (zone 3), sole (zone 4) and
toes (zone 5). Soft-tissue sarcomas arising in zone 1 were
excluded. Sarcomas were staged according to the Ennek-
ing staging system [13].
T h eE t h i c sC o m m i t t e e so fM i eU n i v e r s i t ya p p r o v e d
the study.
Statistical analysis
Data were statistically analyzed using SPSS Statistics ver-
sion 18.0 (SPSS Inc, Chicago, IL). P values below 0.05
were considered significant. All data are expressed as
means ± standard deviation (SD). Associations in data
between the UT and PT groups were determined using an
unpaired t-test or the c
2 test. Actuarial data for overall
and event-free survival rates at the final follow-up were
calculated using Kaplan-Maier analysis.
Results
Table 1 shows details of the 14 patients who were treated
for soft-tissue sarcoma of the foot. The most common
diagnoses were synovial sarcoma in 4 patients and clear
cell sarcoma and rhabdomyosarcoma in one patient each.
Five patients underwent unplanned resection elsewhere
before referral (UT group), and nine underwent biopsy
and surgical excision at our institution (PT group).
Seven patients had wide excision of the tumors or addi-
tional wider excision of lesions that had been inadequately
excised. Six patients had undergone amputation. One
patient died of the disease before undergoing wide resec-
tion. Another patient did not require additional excision
because the estimated surgical margin after the initial exci-
sion was negative. Four patients died due to the sarcoma
and all of them had pulmonary metastasis. One patient
died of other causes. The mean time from surgery to
death was 13.8 months (range 11 - 38).
Chemotherapy was administered to 5 patients with
synovial sarcoma, rhabdomyosarcoma, fibrosarcoma and
leiomyosarcoma. Radiation therapy was administered to
2 patients. Only one patient with high-grade sarcoma
(rhabdomyosarcoma) received both chemotherapy and
radiation therapy. Five did not receive adjuvant che-
motherapy after resection because the histological grade
was low or intermediate.
Figures 1 and 2 show Kaplan-Meier analysis for event-
free and overall survival rates, respectively. The overall
5-year survival rate of all patients was 66.8%. The overall
5-year survival rates for the PT and UT groups were
65.6% and 60.0%, respectively. The overall event-free 5-
year survival rate of all of our patients was 55.0%. The
event-free 5-year survival rates for the PT and UT
groups were 63.5% and 40.0%, respectively. Two devel-
oped local recurrence and six developed lung metas-
tases. Only one patient with clear cell sarcoma had
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rates did not significantly differ between the PT and UT
groups.
Among patient age, gender, tumor location, histologi-
cal grade, tumor size, complications and limb preserva-
tion, only tumor size significantly differed between the
UT and PT groups (p < 0.05).
Discussion
Soft tissue tumors or tumor-like lesion of the foot are
usually histologically benign [4]. Ganglions comprise
about one-third of all soft tissue tumors [5]. Because
patients with asymptomatic small tumors do not often
receive appropriate medical care, the literature does not
always reflect the true proportion of soft-tissue tumors
that are foot sarcomas. However, Berlin [3] identified
449 sarcomas in an analysis of 307,601 tumors and
tumor-like conditions of the foot. Kirby et al. [4]
reviewed 83 patients with soft-tissue tumors and tumor-
like conditions of the foot and ankle and identified 11
(13%) malignant tumors of which synovial sarcoma was
the most frequent. Temple et al. [8] described 12
(34.3%) synovial sarcomas among 39 soft tissue sarco-
mas of the foot and ankle. Thacker et al. [14] described
17 (32.7%) among 52 soft tissue sarcomas and Cribb et
al. [15] found 12 (44.4%) among 27 soft tissue sarcomas.
We found here that synovial sarcomas (n = 4; 28.6%)
comprised the most frequent soft tissue sarcoma of the
foot, even after tumors originating in the ankle were
excluded.
Table 1 Patients’ data
Case Age Sex Diagnosis LC CC Stage FNCLCC grade Size FSM LP Chem RT Follow-up (months) Prog Group
1 25 M RMS 4 Uncertain II-B 3 S amp No No Yes 6 DOD UT
2 46 F SS 5 Mass II-B 3 S amp No Yes No 7 DOD UT
3 50 M LPS 3 Mass I-B 1 B wide Yes No No 24 CDF PT
4 2 F RMS 4 Swelling III-B 3 S no op Yes Yes Yes 11 DOD PT
5 33 M CCS 5 Mass II-B 2 B amp No No No 128 CDF PT
6 41 M SS 4 Mass I-B 2 S ad Yes No No 89 CDF UT
7 10 M FS 3 Mass II-B 2 B wide Yes Yes No 170 CDF PT
8 67 M CSSP 4 Uncertain II-B 2 B amp No No No 7 DOC PT
9 42 M LMS 4 Pain, mass II-B 2 B amp No Yes No 38 DOD PT
10 39 F SS 4 Tenderness II-B 2 B ad Yes Yes No 92 AWD UT
11 47 M SS 4 Mass II-B 3 B amp No No No 110 CDF PT
12 19 F CCS 2 Tenderness II-B 2 S ad Yes No Yes 84 NED UT
13 66 M ESMCS 4 Uncertain I-B 1 B wide Yes No Yes 12 AWD PT
14 14 M DFSP 3 Mass II-A 2 B wide Yes No No 13 CDF PT
Patients are in chronological order. LC, location; CC, chief complaint; FNCLCC grade, Fédération Nationale des Centres de Lutte Contre le Cancer Grading System;
FSM, final surgical margin; LP, limb preservation; Chem, chemotherapy; RT, radiation therapy; Prog, Prognosis. CCS, Clear cell sarcoma; CSSP, chondrosarcoma of
soft part; DFSP, dermatofibrosarcoma protuberance; ESMCS, extraskeletal myxoid chondrosarcoma; FS, fibrosarcoma; LMS, leiomyosarcoma; LPS, liposarocoma;
RMS, rhabdomyosarcoma; SS, synovial sarcoma. Tumor size: S, < 3 cm; B, ≥3 cm; amp, amputation; wide, wide resection; no op, no operation; ad, additional
wider resection; AWD, alive with disease; CDF, complete disease free; NED, no evidence of disease; DOD, died of disease; DOC, died of other causes. PT, planned
excision; UT, unplanned excision.
Figure 1 Kaplan-Meier overall survival estimates for unplanned
and planned excisions of foot sarcoma. No significant differences
between PT and UT groups. PT, planned excision; UT, unplanned
excision.
Figure 2 Kaplan-Meier event-free survival estimates for
unplanned and planned excisions of foot sarcoma.N o
significant differences between PT and UT groups. PT, planned
excision; UT, unplanned excision.
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located in the distal extremity compared with the proximal
extremity. Zeytoonjian et al. [16] described that the overall
death rate all sarcomas was 26.6% (630/2367 patients),
whereas that of foot sarcoma was 10.3% (18/170 patients).
Cribb et al. [15] reported a rate of 14.8% (4/27 patients).
Thacker et al. [14] indicated a 5-year survival rate of 78.2%
(11/52 patients) among 52 patients. The 5-year survival
rate of 66.8% (4/14 patients) in the present study was rela-
tively lower than those described by others [14-16]. How-
ever, the 5-year survival rate of latest five patients was
100%. We speculated that improvements in diagnostic
imaging technology including MRI enabled accurate preo-
perative evaluation of tumors. MRI is useful to know
tumor size, tumor location and tumor margin. And, we
believe that preoperative MRI is useful for evaluating and
diagnosing foot tumors, because most of the benign soft-
tissue tumors that frequently occur on the foot, such as
schwannoma, epidermal cysts, ganglion cysts, lipomas and
hemangiomas, can be diagnosed using MR imaging [3-5].
For the diagnosis of schwannoma, Tinel’s-like sign with
specific MRI findings (target sign) may be useful. In the
case of epidermal cysts, T1-weighted images after gadoli-
nium administration show rim-enhancement with subcu-
taneous involvement. Ganglion cysts can be easily
diagnosed because of the homogenous intensity of the
lesion. Lipomas can also be easily diagnosed due to their
homogeneous high-intensi t ya r e ao nb o t hT 1 - a n dT 2 -
weighted images. Although hemangioma is sometimes dif-
ficult to distinguish from malignancy, the MR findings
often show lobulation, septation, and central low-signal-
intensity dots with small fat intensity foci. On the contrary,
when a definite imaging diagnosis can not be obtained, the
surgeon should carefully excise the tumor after consider-
ing the possibility of malignancy, even if the tumor size is
small. These preoperative imaging analyses might have
been associated with a good clinical result.
Five (35.7%) of 14 patients in the present study had
unplanned excisions. However, Davis et al. [6] and Good-
lad et al. [10] reported that 43.5% and 40% of patients with
soft-tissue sarcomas in their series, respectively, underwent
unplanned resections; our findings were comparable to
these results. The physical features of soft tissue sarcomas
of the foot, including palpable mass, swelling, local
warmth, and pain, are similar to those of benign lesions,
and thus many smaller lesions tend to undergo simple
unplanned excisions without appropriate diagnostic ima-
ging and biopsies. These non-specific features might in
part facilitate the high incidence of unplanned surgical
excisions. Indeed, tumors were significantly smaller in the
UT group than in the PT group in the present series. This
result might paradoxically show that smaller tumors throw
clinicians off guard. An excisional biopsy may be justified
when the tumor is less than 3 cm. However, the problem
is whether the initial surgery was performed while consid-
ering the possibility of malignancy. Unfortunately, in this
study, all of the UT group patients were initially treated
without considering the possibility of malignancy, and this
led to extensive hematoma formation, inappropriate drai-
nage and improper skin incisions. Therefore, we classified
the cases initially treated by general surgeons or general
orthopaedic surgeon without considering the possibility of
malignancy as part of the UT group.
Unplanned excisions of soft tissue sarcomas are fre-
quent, but their influence on local recurrence, distant
metastasis and patient survival remains controversial
[17-19]. Davis et al. [6] compared the clinical outcomes
between patients primarily treated at an institution specia-
lizing in cancer and those who were referred following
unplanned excision at a general hospital. They found a
higher local recurrence rate in the group with unplanned
surgical excisions, especially those with residual tumors in
re-resected specimens. Clasby et al. [9] reviewed 377
patients with primary soft-tissue sarcomas, and estimated
that 21.3% (80/377 patients) of them had been inade-
quately treated. Furthermor e ,t h e yn o t e dap o o r e ro u t -
come among patients with tumors that recurred after
marginal excision. Thacker et al. [14] reported 5-year
oncological survival rates of 80.4% (21/23 patients) and
73.4% (22/29 patients) in patients who underwent planned
and unplanned excisions, respectively, and 5-year event
free survival rates of 68.1% (9/23 patients) and 60.8% (11/
23 patients), respectively. Temple et al. [8] reported 4-year
oncologic survival rates of 76.5% (13/17 patients) and
77.8% (12/18 patients) in the PT and UT groups, respec-
tively, and local recurrence rates of 11.8% (2/17 patients)
and 16.7% (3/18 patients), respectively.
In the present series, 5-year overall survival rate in the
PT group was 65.6% (7/9 patients) and that in the UT
group was 60.0% (3/5 patients). The 5-year event free sur-
vival rates were 63.5% (6/9 patients) and 40.0% (2/5
patients) in the PT and UT groups, respectively. Rates of
tumor recurrence or tumor death did not significantly dif-
fer between the UT and PT groups. However, tumors
w e r es i g n i f i c a n t l yl a r g e ri nt h eP Tg r o u pt h a ni nt h eU T
group in this study. Larger tumors significantly and nega-
tively affect prognosis in patients with soft tissue sarcoma
[20,21]. These findings suggested a relatively worse prog-
nosis for the UT group than for the PT group. Because
the absence of a statistical difference was probably due to
the low number of recurrences and metastasis in the pre-
sent study, further large-scale studies are warranted.
In point of the anatomical site of foot sarcoma, dorsal
side (location 3) sarcomas of the foot were all big size (> 3
cm), On the other side, plantar side (loation 2 and 4) sar-
comas of the foot were 4/9 cases small size and 5/9 big
size. Thus, dorsal side sarcomas of the foot tend to be
neglect until the tumor grew big size. Patients who have
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earlier, because they might feel discomfort and pain of
their sole.
The major shortcoming of this study was the limited
patient population, because soft tissue sarcoma of the
foot is extremely rare. Therefore, the statistical power of
this study is very low.
Most soft tissue tumors of the foot are small and benign,
which results in frequent unplanned excisions. Although
benign tumors would not pose a clinical problem, malig-
nant tumors lead to a higher incidence of local recurrence
even after additional surgery and result in a poor prog-
nosis. We emphasize that unplanned excisions should be
averted by appropriate preoperative evaluation such as by
MRI, early referral of all potential malignancies to a cancer
center, biopsy assessment and wide excision of malignant
lesions.
Conclusions
Sarcomas of the foot are rare and thus tend not to be sus-
pected by either patients or clinicians. Event-free and over-
all survival rates did not significantly differ between the PT
and UT groups, but tumors were significantly larger in the
PT group. Larger tumors negatively affect the prognosis in
patients with soft tissue sarcoma. Therefore, we concluded
that the UT group had a relatively worse prognosis than
the PT group. Therefore, we conclude that unplanned
resection leads to a relatively worse prognosis and a likeli-
hood of recurrence despite additional resections. We
recommend that even small soft tumors of the foot should
be preoperatively evaluated by imaging to avoid repeated
local recurrence.
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